Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological and predictive role of ERCC1 polymorphisms in cancer.

Critical reviews in oncology/hematology - 1 Mar 2017

Formica V, Doldo E, Antonetti F R, Nardecchia A, Ferroni P, Riondino S, Morelli C, Arkenau H T, Guadagni F, Orlandi A, Roselli M

Abstract excerpt

Excision repair cross-complementation group 1 (ERCC1) is a key component in DNA repair mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent oxaliplatin. Germline ERCC1 polymorphisms may alter the protein expression and published data on their predictive and prognostic value have so far been contradictory. In the present article we review available evidence on the clinical role...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to DNA Repair

Share to Endonucleases

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Replication Protein C

Source

Identifiers

PMID: 28259288
DOI: 10.1016/j.critrevonc.2017.01.016

Genes

ERCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological and predictive role of ERCC1 polymorphisms in cancer.PMID 28259288Read ↗

ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?Semantic proximity Read ↗

XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.Semantic proximity Read ↗

ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.Semantic proximity Read ↗

Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.Semantic proximity Read ↗

ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.Semantic proximity Read ↗

Interethnic variability of ERCC2 polymorphisms.Semantic proximity Read ↗

XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.Semantic proximity Read ↗

[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].Semantic proximity Read ↗

Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.Semantic proximity Read ↗

Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.Semantic proximity Read ↗

Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin‐based chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.